The strong clinical data and extended cash runway support continued development, but the significant increase in losses and dilution from the $164M offering may pressure shares near-term. Monitor upcoming clinical presentations in 2026 for further validation of VMT-α-NET and combination data for VMT01 with nivolumab.
Price Chart
Executive Summary
Perspective Therapeutics (CATX) reported full-year 2025 financial results and provided a clinical update on its radiopharmaceutical pipeline. The company highlighted positive safety and efficacy data from its lead VMT-α-NET program in neuroendocrine tumors, with durable disease control and deepening responses. It also announced a $164 million equity raise, extending its cash runway into late 2027. However, net loss widened to $103.1 million in 2025 from $79.3 million in 2024, driven by higher R&D spending and a $10M asset impairment.
Key Financial Metrics
Key Facts
- VMT-α-NET showed favorable tolerability and 39% confirmed response rate in Cohort 2 (5.0 mCi) with deepening responses over time
- Cash, cash equivalents, and short-term investments were $145M as of December 31, 2025; $164M raised in February 2026 offering
- Cash runway now extends into late 2027
- Net loss increased to $103.1M in 2025 from $79.3M in 2024, with EPS of -$1.40 vs. -$1.23
- R&D expenses doubled to $84.2M in 2025, including a $10M non-cash impairment loss
- Clinical updates for all three programs (VMT-α-NET, VMT01, PSV359) expected at medical conferences in 2026
Financial Impact
Net loss increased by 30% YoY to $103.1M; R&D expenses up 102% to $84.2M; $164M in net proceeds from equity offering
Risk Factors
- High cash burn and increasing net losses despite recent funding
- Dilution from 39.6M shares and 6.6M pre-funded warrants issued in February 2026 offering
- Clinical development risks in early-stage oncology programs with no guaranteed regulatory path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256714 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 19d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers